ClinicalTrials.gg
CompletedNCT04206553LIBERTY-BPUpdated Jun 18, 2026Results posted

A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid

A Phase 2/3 interventional study of dupilumab and Matching Placebo in Bullous Pemphigoid, sponsored by Regeneron Pharmaceuticals. Completed at 53 sites in 9 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Regeneron Pharmaceuticals · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Pemphigoid, Bullous with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Pemphigoid, Bullous · United States.

Enrollment
2nd of 13
106 · median 11
Started
2020
the only one that year
Phase 2/3
2 of 15
none open now
Registered
9th of 15
by date
Lead sponsor
1 of 15
Regeneron Pharmaceuticals

Among the 15 studies in Pemphigoid, Bullous with a site in United States, this one is the 2nd largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2020, is one of 2 in phase 2/3, and was the 9th registered.

Pemphigoid, Bullous

64 studies on the registry are indexed under Pemphigoid, Bullous; 8 are open to participants now.

Browse Pemphigoid, Bullous studies →

Open to participants now

2 of the 15 studies in Pemphigoid, Bullous with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Pemphigoid, Bullous studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Pemphigoid, Bullous with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this study is to investigate whether dupilumab is effective and safe for the treatment of bullous pemphigoid. Dupilumab is a type of drug called a "monoclonal antibody". An antibody is a special kind of protein that the immune (defense) system normally makes to fight bacteria and viruses. Bullous pemphigoid is an autoimmune subepidermal blistering disease, predominately affecting the elderly (typical onset after age 60).

The study is looking at several other research questions, including:

  • Side effects that may be experienced by people taking dupilumab
  • How dupilumab works in the body and affects the body
  • How dupilumab affects quality of life
  • How much dupilumab is present in the blood
  • To see if dupilumab works to wean the patient off oral corticosteroids
03

Conditions studied

  • Bullous Pemphigoid

Browse trials for

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patients must have characteristic clinical features of bullous pemphigoid (BP) (eg, urticarial or eczematous or erythematous plaques, bullae, pruritus) at the screening and baseline visits.
  • Study participants are required to have a confirmed diagnosis of BP based on histopathology, immunopathology, and serology at the baseline visit, as defined in the protocol.
  • Bullous Pemphigoid Disease Area Index (BPDAI) activity score ≥24 at baseline and screening visits.
  • Baseline peak pruritus NRS score for maximum itch intensity ≥4
  • performance status score ≥50% at the screening visit.

Key Exclusion Criteria:

  • Forms of pemphigoid other than classic BP (eg, Brunsting-Perry cicatricial pemphigoid, anti-p200 pemphigoid, epidermolysis bullosa acquisita, or BP with concomitant pemphigus vulgaris)
  • Patients who are receiving treatments known to cause or exacerbate BP (eg, angiotensin converting enzyme inhibitors, penicillamine, furosemide, phenacetin, dipeptidyl peptidase 4 inhibitor) who have not been on a stable dose of these medications for at least 4 weeks prior to the screening visit
  • Have ever received treatment with an IL-4 or IL-13 antagonist such as dupilumab, tralokinumab, or lebrikizumab.
  • Treatment with systemic within 7 days before the baseline visit
  • Treatment with topical corticosteroids of medium potency or higher, topical calcineurin inhibitor, or topical crisaborole within 7 days before the baseline visit
  • Treatment with non-steroidal /immunomodulating drug(s) (eg, mycophenolate mofetil, azathioprine, or methotrexate) within 4 weeks before the baseline visit.
  • Treatment with BP-directed biologics as follows:
  • Any cell-depleting agents including but not limited to rituximab: within 12 months before the baseline visit, or until lymphocyte and CD 19+ lymphocyte count returns to normal, whichever is longer
  • Other biologics (such as IL-5 inhibitors benralizumab or mepolizumab): within 5 half-lives (if known) or 16 weeks prior to the baseline visit, whichever is longer
  • Intravenous immunoglobulin within 16 weeks prior to the baseline visit

NOTE: Other Protocol Defined Inclusion/Exclusion Criteria Apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    dupilumab

    Drug: dupilumab · Drug: Oral corticosteroids (OCS)

  • Experimental
    Matching placebo

    Drug: Matching Placebo · Drug: Oral corticosteroids (OCS)

Interventions

  • Loading dose administered subcutaneous (SC), followed by SC once every 2 weeks (Q2W) dosing.

    Also known as: Dupixent®, REGN668, SAR231893

  • DrugMatching Placebo

    Matching dupilumab without active substance

  • DrugOral corticosteroids (OCS)

    Prednisone or prednisolone per standard of care to obtain control of disease activity.

06

What researchers measure

Primary outcomes

  1. Percent of Participants Achieving Sustained Remission at Week 36

    Sustained remission at week 36, defined as: (1) Complete remission (absence of new lesions \& epithelialization of old lesions) \& off oral corticosteroids (OCS) no later than week 16 \& (2) Absence of disease relapse (appearance of ≥3 new lesions a month \[blisters, eczematous lesions, or urticarial plaques\] or at least 1 large eczematous lesion or urticarial plaque that does not heal within 1 week) after completion of OCS taper, no later than week 16, to week 36 \& (3) Absence of need for rescue therapy during 36 weeks (rescue therapy includes increase of OCS dose during the taper, re-initiation of OCS after completion of the OCS taper, or initiation of any BP-directed therapy). Participants with missing sustained remission data at week 36 due to discontinuation due to lack of efficacy, treatment-related AE, or death were considered non-responders \& those with missing data due to other reasons were handled using multiple imputation.

    Time frame: At Week 36

Secondary outcomes

  1. Total Cumulative Dose of Oral Corticosteroids (OCS) From Baseline to Week 36

    All participants in both treatment groups were started on OCS at randomization (day 1) with taper beginning no later than week 6 with the objective to taper off by week 16. OCS could be used as rescue treatment for loss of disease control/ disease relapse during the study. Days after non-OCS systemic rescue treatment use were imputed by the worst observation carried forward (WOCF) method (i.e., the highest daily OCS dose prior to any non-OCS systemic rescue treatment use). Missing data after study discontinuation were imputed with the average daily OCS dose among week 36 completers in each treatment group.

    Time frame: Week 36

  2. Percent Change in Weekly Average of Daily Peak Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 36

    Peak pruritus NRS was used by participants to rate the intensity of pruritus during the past 24 hours, with 0 indicating no itch and 10 indicating worst itch possible. Participants were required to have a baseline peak pruritus NRS maximum intensity average of ≥4 during the 7 days prior to randomization for eligibility. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.

    Time frame: Baseline, Week 36

  3. Percent of Participants With Improvement (Reduction) of Weekly Average of Daily Peak Pruritus NRS ≥4 From Baseline to Week 36

    Peak pruritus NRS was used by participants to rate the intensity of pruritus during the past 24 hours, with 0 indicating no itch and 10 indicating worst itch possible. Participants were required to have a baseline peak pruritus NRS maximum intensity average of ≥4 during the 7 days prior to randomization for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 36 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the weekly average of daily peak pruritus NRS.

    Time frame: Baseline, Week 36

  4. Percent Change in Bullous Pemphigoid Disease Area Index (BPDAI) Activity Score From Baseline to Week 36

    BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.

    Time frame: Baseline, Week 36

  5. Time to First Use of Rescue Medication Up to Week 36

    Participants were considered to have used rescue treatment at the time of discontinuation from the study due to lack of efficacy, treatment-related AE, or death. Participants were censored at the time of discontinuation from the study due to other reasons. Restricted mean event time and corresponding standard error (SE) are based on the Kaplan-Meier method. The restricted mean event time was calculated up to study day 253 (i.e., week 36).

    Time frame: Up to Week 36

  6. Duration of Complete Remission While Not Requiring OCS Up to Week 36

    Complete remission was defined as absence of new lesions and epithelialization of old lesions. Participants were considered as not achieving complete remission after rescue treatment use. Participants with missing assessment of complete remission caused by discontinuation from the study before week 36 due to lack of efficacy, treatment-related AE, or death were considered as not achieving complete remission. Participants with missing assessment of complete remission due to other reasons were imputed using multiple imputation.

    Time frame: Up to Week 36

  7. Percent of Participants Who Did Not Achieve Control of Disease Activity Before Week 36

    Control of disease activity was defined as absence of new lesions and existing lesions beginning to heal. Participants who achieved initial control of disease activity after rescue treatment use were considered to not have achieved control of disease activity before week 36. Participants whose response status could not be determined due to missing data were considered to not have achieved control of disease activity before week 36.

    Time frame: Up to Week 36

  8. Percent of Participants Who Relapsed After Achieving Control of Disease Activity Up to Week 36

    Relapse was defined as the appearance of 3 or more new lesions a month (blisters, eczematous lesions, or urticarial plaques) or at least 1 large (\>10 centimeters \[cm\] diameter) eczematous lesion or urticarial plaque that does not heal within 1 week. Control of disease activity was defined as absence of new lesions and existing lesions beginning to heal. Participants who used rescue treatment were considered to have relapsed after achieving control of disease activity. Participants whose response status could not be determined due to missing data were considered to have relapsed after achieving control of disease activity.

    Time frame: Up to Week 36

  9. Percent of Participants Who Did Not Achieve Complete Remission Before Week 36

    Complete remission was defined as absence of new lesions and epithelialization of old lesions. Participants who achieved initial complete remission after rescue treatment use were considered to not have achieved complete remission before week 36. Participants whose response status could not be determined due to missing data were considered to not have achieved complete remission before week 36.

    Time frame: Up to Week 36

  10. Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥50% From Baseline to Week 36

    BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 36 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.

    Time frame: Baseline, Week 36

  11. Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥75% From Baseline to Week 36

    BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 36 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.

    Time frame: Baseline, Week 36

  12. Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥90% From Baseline to Week 36

    BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 36 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.

    Time frame: Baseline, Week 36

  13. Change in Autoimmune Bullous Disease Quality of Life (ABQOL) Score From Baseline to Week 36

    ABQOL questionnaire consists of 17 items, which encompass physical burden of the disease, psychiatric effects, and effects on daily life functioning. Each question ranges from 0 to 3 points, with higher scores indicating poorer quality of life. The maximum ABQOL score is 51. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.

    Time frame: Baseline, Week 36

  14. Change in Percent Body Surface Area (BSA) of BP Involvement From Baseline to Week 36

    Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.

    Time frame: Baseline, Week 36

  15. Change in BP180 Immunoglobulin G (IgG) Autoantibody Titer From Baseline to Week 36

    Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.

    Time frame: Baseline, Week 36

  16. Change in BP230 IgG Autoantibody Titer From Baseline to Week 36

    Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.

    Time frame: Baseline, Week 36

  17. Percent of Participants Achieving Sustained Remission at Week 52

    Sustained remission at week 52, defined as: (1) Complete remission (absence of new lesions \& epithelialization of old lesions) \& off OCS no later than week 16 \& (2) Absence of disease relapse (appearance of ≥3 new lesions a month \[blisters, eczematous lesions, or urticarial plaques\] or at least 1 large eczematous lesion or urticarial plaque that does not heal within 1 week) after completion of OCS taper, no later than week 16, to week 52 \& (3) Absence of need for rescue therapy during 52 weeks (rescue therapy includes increase of OCS dose during the taper, re-initiation of OCS after completion of the OCS taper, or initiation of any BP-directed therapy). Participants with missing sustained remission data at week 52 due to discontinuation due to lack of efficacy, treatment-related AE, or death were considered non-responders \& those with missing data due to other reasons were handled using multiple imputation.

    Time frame: At Week 52

  18. Total Cumulative Dose of OCS From Baseline to Week 52

    All participants in both treatment groups were started on OCS at randomization (day 1) with taper beginning no later than week 6 with the objective to taper off by week 16. OCS could be used as rescue treatment for loss of disease control/ disease relapse during the study. Days after non-OCS systemic rescue treatment use were imputed by the WOCF method (i.e., the highest daily OCS dose prior to any non-OCS systemic rescue treatment use). Missing data after study discontinuation were imputed with the average daily OCS dose among week 52 completers in each treatment group.

    Time frame: Week 52

  19. Duration of Complete Remission While Not Requiring OCS Up to Week 52

    Complete remission was defined as absence of new lesions and epithelialization of old lesions. Participants were considered as not achieving complete remission after rescue treatment use. Participants with missing assessment of complete remission caused by discontinuation from the study before week 52 due to lack of efficacy, treatment-related AE, or death were considered as not achieving complete remission. Participants with missing assessment of complete remission due to other reasons were imputed using multiple imputation.

    Time frame: Up to Week 52

  20. Percent of Participants Who Did Not Achieve Control of Disease Activity Before Week 52

    Control of disease activity was defined as absence of new lesions and existing lesions beginning to heal. Participants who achieved initial control of disease activity after rescue treatment use were considered to not have achieved control of disease activity before week 52. Participants whose response status could not be determined due to missing data were considered to not have achieved control of disease activity before week 52.

    Time frame: Up to Week 52

  21. Percent of Participants Who Relapsed After Achieving Control of Disease Activity Up to Week 52

    Relapse was defined as the appearance of 3 or more new lesions a month (blisters, eczematous lesions, or urticarial plaques) or at least 1 large (\>10 cm diameter) eczematous lesion or urticarial plaque that does not heal within 1 week. Control of disease activity was defined as absence of new lesions and existing lesions beginning to heal. Participants who used rescue treatment were considered to have relapsed after achieving control of disease activity. Participants whose response status could not be determined due to missing data were considered to have relapsed after achieving control of disease activity.

    Time frame: Up to Week 52

  22. Percent of Participants Who Did Not Achieve Complete Remission Before Week 52

    Complete remission was defined as absence of new lesions and epithelialization of old lesions. Participants who achieved initial complete remission after rescue treatment use were considered to not have achieved complete remission before week 52. Participants whose response status could not be determined due to missing data were considered to not have achieved complete remission before week 52.

    Time frame: Up to Week 52

  23. Percent Change in Weekly Average of Daily Peak Pruritus NRS From Baseline to Week 52

    Peak pruritus NRS was used by participants to rate the intensity of pruritus during the past 24 hours, with 0 indicating no itch and 10 indicating worst itch possible. Participants were required to have a baseline peak pruritus NRS maximum intensity average of ≥4 during the 7 days prior to randomization for eligibility. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 52. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.

    Time frame: Baseline, Week 52

  24. Percent of Participants With Improvement (Reduction) of Weekly Average of Daily Peak Pruritus NRS ≥4 From Baseline to Week 52

    Peak pruritus NRS was used by participants to rate the intensity of pruritus during the past 24 hours, with 0 indicating no itch and 10 indicating worst itch possible. Participants were required to have a baseline peak pruritus NRS maximum intensity average of ≥4 during the 7 days prior to randomization for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 52 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the weekly average of daily peak pruritus NRS.

    Time frame: Baseline, Week 52

  25. Percent Change in BPDAI Activity Score From Baseline to Week 52

    BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 52. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.

    Time frame: Baseline, Week 52

  26. Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥50% From Baseline to Week 52

    BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 52 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.

    Time frame: Baseline, Week 52

  27. Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥75% From Baseline to Week 52

    BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 52 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.

    Time frame: Baseline, Week 52

  28. Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥90% From Baseline to Week 52

    BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 52 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.

    Time frame: Baseline, Week 52

  29. Change in ABQOL Score From Baseline to Week 52

    ABQOL questionnaire consists of 17 items, which encompass physical burden of the disease, psychiatric effects, and effects on daily life functioning. Each question ranges from 0 to 3 points, with higher scores indicating poorer quality of life. The maximum ABQOL score is 51. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 52. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.

    Time frame: Baseline, Week 52

  30. Change in Percent BSA of BP Involvement From Baseline to Week 52

    Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 52. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.

    Time frame: Baseline, Week 52

  31. Change in BP180 IgG Autoantibody Titer From Baseline to Week 52

    Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 52. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.

    Time frame: Baseline, Week 52

  32. Change in BP230 IgG Autoantibody Titer From Baseline to Week 52

    Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 52. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.

    Time frame: Baseline, Week 52

  33. Percent of Participants in Complete Remission and Off OCS No Later Than Week 16

    Complete remission was defined as absence of new lesions and epithelialization of old lesions. Participants were considered non-responders after rescue treatment use. Participants with missing assessment of complete remission caused by discontinuation from the study before week 16 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Participants with missing assessment of complete remission before week 16 due to other reasons were imputed using multiple imputation.

    Time frame: Up to Week 16

  34. Percent Change in BPDAI Activity Score From Baseline to Week 16

    BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.

    Time frame: Baseline, Week 16

  35. Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥50% From Baseline to Week 16

    BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 16 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.

    Time frame: Baseline, Week 16

  36. Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥75% From Baseline to Week 16

    BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 16 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.

    Time frame: Baseline, Week 16

  37. Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥90% From Baseline to Week 16

    BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 16 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.

    Time frame: Baseline, Week 16

  38. Percent Change in Weekly Average of Daily Peak Pruritus NRS From Baseline to Week 16

    Peak pruritus NRS was used by participants to rate the intensity of pruritus during the past 24 hours, with 0 indicating no itch and 10 indicating worst itch possible. Participants were required to have a baseline peak pruritus NRS maximum intensity average of ≥4 during the 7 days prior to randomization for eligibility. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.

    Time frame: Baseline, Week 16

  39. Percent of Participants With Improvement (Reduction) of Weekly Average of Daily Peak Pruritus NRS ≥4 From Baseline to Week 16

    Peak pruritus NRS was used by participants to rate the intensity of pruritus during the past 24 hours, with 0 indicating no itch and 10 indicating worst itch possible. Participants were required to have a baseline peak pruritus NRS maximum intensity average of ≥4 during the 7 days prior to randomization for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 16 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the weekly average of daily peak pruritus NRS.

    Time frame: Baseline, Week 16

  40. Number of Participants With At Least One Treatment-emergent Adverse Event (TEAE) Through Week 52

    Time frame: Through Week 52

  41. Number of Participants With At Least One Serious TEAE Through Week 52

    Time frame: Through Week 52

  42. Number of Participants With At Least One TE Adverse Event of Special Interest (AESI) Through Week 52

    Time frame: Through Week 52

  43. Number of Participants With At Least One TEAE Through Week 64

    Time frame: Week 52 through Week 64

  44. Number of Participants With At Least One Serious TEAE Through Week 64

    Time frame: Week 52 through Week 64

  45. Number of Participants With At Least One TE AESI Through Week 64

    Time frame: Week 52 through Week 64

  46. Concentrations of Functional Dupilumab in Serum

    Time frame: Baseline to Week 64

  47. Number of Participants With TE Anti-drug Antibody (ADA) Response Per Maximum Titer Category

    Time frame: Baseline to Week 64

Other outcomes

  1. Supplemental Analysis of Total Cumulative Dose of OCS From Baseline to Week 36

    All participants in both treatment groups were started on OCS at randomization (day 1) with taper beginning no later than week 6 with the objective to taper off by week 16. OCS could be used as rescue treatment for loss of disease control/ disease relapse during the study. Days after non-OCS systemic rescue treatment use were imputed by the WOCF method (i.e., the highest daily OCS dose prior to any non-OCS systemic rescue treatment use). Missing data after study discontinuation were imputed with the average daily OCS dose among week 36 completers in each treatment group. Median total cumulative dose of OCS from baseline to week 36 reported.

    Time frame: Week 36

07

Results

Posted Mar 6, 2026

Participant flow

Participant flow — Overall Study
MilestonePlaceboDupilumab Q2W
Started5353
Completed3245
Not completed218
Withdrew: Adverse event62
Withdrew: Lack of efficacy51
Withdrew: Physician decision01
Withdrew: Withdrawal by subject83
Withdrew: Death21

Outcome measures

PrimaryPercent of Participants Achieving Sustained Remission at Week 36

Sustained remission at week 36, defined as: (1) Complete remission (absence of new lesions \& epithelialization of old lesions) \& off oral corticosteroids (OCS) no later than week 16 \& (2) Absence of disease relapse (appearance of ≥3 new lesions a month \[blisters, eczematous lesions, or urticarial plaques\] or at least 1 large eczematous lesion or urticarial plaque that does not heal within 1 week) after completion of OCS taper, no later than week 16, to week 36 \& (3) Absence of need for rescue therapy during 36 weeks (rescue therapy includes increase of OCS dose during the taper, re-initiation of OCS after completion of the OCS taper, or initiation of any BP-directed therapy). Participants with missing sustained remission data at week 36 due to discontinuation due to lack of efficacy, treatment-related AE, or death were considered non-responders \& those with missing data due to other reasons were handled using multiple imputation.

Time frame:
At Week 36
Reported as:
Number · Estimated Percentage of Participants
Percent of Participants Achieving Sustained Remission at Week 36
Estimated Percentage of ParticipantsPlaceboDupilumab Q2W
Percent of Participants Achieving Sustained Remission at Week 364.018.2
Statistical analysis
  • Placebo vs Dupilumab Q2W · Barnard's exact test · p = 0.0250 (multiplicity-controlled) · Risk difference (rd): 14.2 · 95% CI 1.97 to 27.74Dupilumab minus Placebo
SecondaryTotal Cumulative Dose of Oral Corticosteroids (OCS) From Baseline to Week 36

All participants in both treatment groups were started on OCS at randomization (day 1) with taper beginning no later than week 6 with the objective to taper off by week 16. OCS could be used as rescue treatment for loss of disease control/ disease relapse during the study. Days after non-OCS systemic rescue treatment use were imputed by the worst observation carried forward (WOCF) method (i.e., the highest daily OCS dose prior to any non-OCS systemic rescue treatment use). Missing data after study discontinuation were imputed with the average daily OCS dose among week 36 completers in each treatment group.

Time frame:
Week 36
Reported as:
Least squares mean · milligrams (mg)
Total Cumulative Dose of Oral Corticosteroids (OCS) From Baseline to Week 36
milligrams (mg)PlaceboDupilumab Q2W
Total Cumulative Dose of Oral Corticosteroids (OCS) From Baseline to Week 365121.15 ± 473.0344184.93 ± 454.733
Statistical analysis
  • Placebo vs Dupilumab Q2W · ANCOVA · p = 0.1092 (multiplicity-controlled) · Ls mean difference: -936.21 · 95% CI -2085.387 to 212.961Dupilumab minus Placebo
SecondaryPercent Change in Weekly Average of Daily Peak Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 36

Peak pruritus NRS was used by participants to rate the intensity of pruritus during the past 24 hours, with 0 indicating no itch and 10 indicating worst itch possible. Participants were required to have a baseline peak pruritus NRS maximum intensity average of ≥4 during the 7 days prior to randomization for eligibility. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · Percentage of Change
Percent Change in Weekly Average of Daily Peak Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 36
Percentage of ChangePlaceboDupilumab Q2W
Percent Change in Weekly Average of Daily Peak Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 36-26.7 ± 6.59-51.8 ± 6.66
Statistical analysis
  • Placebo vs Dupilumab Q2W · ANCOVA · p = 0.0025 (multiplicity-controlled) · Ls mean difference: -25.2 · 95% CI -41.47 to -8.85Dupilumab minus Placebo
SecondaryPercent of Participants With Improvement (Reduction) of Weekly Average of Daily Peak Pruritus NRS ≥4 From Baseline to Week 36

Peak pruritus NRS was used by participants to rate the intensity of pruritus during the past 24 hours, with 0 indicating no itch and 10 indicating worst itch possible. Participants were required to have a baseline peak pruritus NRS maximum intensity average of ≥4 during the 7 days prior to randomization for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 36 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the weekly average of daily peak pruritus NRS.

Time frame:
Baseline, Week 36
Reported as:
Number · Estimated Percentage of Participants
Percent of Participants With Improvement (Reduction) of Weekly Average of Daily Peak Pruritus NRS ≥4 From Baseline to Week 36
Estimated Percentage of ParticipantsPlaceboDupilumab Q2W
Percent of Participants With Improvement (Reduction) of Weekly Average of Daily Peak Pruritus NRS ≥4 From Baseline to Week 3610.539.8
Statistical analysis
  • Placebo vs Dupilumab Q2W · Barnard's exact test · p = 0.0006 (multiplicity-controlled) · Risk difference (rd): 29.3 · 95% CI 12.79 to 45.04Dupilumab minus Placebo
SecondaryPercent Change in Bullous Pemphigoid Disease Area Index (BPDAI) Activity Score From Baseline to Week 36

BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · Percentage of Change
Percent Change in Bullous Pemphigoid Disease Area Index (BPDAI) Activity Score From Baseline to Week 36
Percentage of ChangePlaceboDupilumab Q2W
Percent Change in Bullous Pemphigoid Disease Area Index (BPDAI) Activity Score From Baseline to Week 36-50.5 ± 7.04-76.7 ± 6.89
Statistical analysis
  • Placebo vs Dupilumab Q2W · ANCOVA · p = 0.0021 (multiplicity-controlled) · Ls mean difference: -26.2 · 95% CI -42.83 to -9.50Dupilumab minus Placebo
SecondaryTime to First Use of Rescue Medication Up to Week 36

Participants were considered to have used rescue treatment at the time of discontinuation from the study due to lack of efficacy, treatment-related AE, or death. Participants were censored at the time of discontinuation from the study due to other reasons. Restricted mean event time and corresponding standard error (SE) are based on the Kaplan-Meier method. The restricted mean event time was calculated up to study day 253 (i.e., week 36).

Time frame:
Up to Week 36
Reported as:
Mean · Days
Time to First Use of Rescue Medication Up to Week 36
DaysPlaceboDupilumab Q2W
Time to First Use of Rescue Medication Up to Week 36126.8 ± 8.17168.9 ± 10.96
Statistical analysis
  • Placebo vs Dupilumab Q2W · Cox proportional hazards model · p = 0.0023 (multiplicity-controlled) · Hazard ratio (hr): 0.48 · 95% CI 0.300 to 0.770Dupilumab vs. Placebo
SecondaryDuration of Complete Remission While Not Requiring OCS Up to Week 36

Complete remission was defined as absence of new lesions and epithelialization of old lesions. Participants were considered as not achieving complete remission after rescue treatment use. Participants with missing assessment of complete remission caused by discontinuation from the study before week 36 due to lack of efficacy, treatment-related AE, or death were considered as not achieving complete remission. Participants with missing assessment of complete remission due to other reasons were imputed using multiple imputation.

Time frame:
Up to Week 36
Reported as:
Least squares mean · Days
Duration of Complete Remission While Not Requiring OCS Up to Week 36
DaysPlaceboDupilumab Q2W
Duration of Complete Remission While Not Requiring OCS Up to Week 3612.9 ± 8.0838.7 ± 7.88
Statistical analysis
  • Placebo vs Dupilumab Q2W · ANCOVA · p = 0.0112 · Ls mean difference: 25.7 · 95% CI 5.85 to 45.63Dupilumab minus Placebo
SecondaryPercent of Participants Who Did Not Achieve Control of Disease Activity Before Week 36

Control of disease activity was defined as absence of new lesions and existing lesions beginning to heal. Participants who achieved initial control of disease activity after rescue treatment use were considered to not have achieved control of disease activity before week 36. Participants whose response status could not be determined due to missing data were considered to not have achieved control of disease activity before week 36.

Time frame:
Up to Week 36
Reported as:
Number · Percentage of Participants
Percent of Participants Who Did Not Achieve Control of Disease Activity Before Week 36
Percentage of ParticipantsPlaceboDupilumab Q2W
Percent of Participants Who Did Not Achieve Control of Disease Activity Before Week 367.51.9
Statistical analysis
  • Placebo vs Dupilumab Q2W · Barnard's exact test · p = 0.2414 · Risk difference (rd): -5.7 · 95% CI -16.31 to 3.34Dupilumab minus Placebo
SecondaryPercent of Participants Who Relapsed After Achieving Control of Disease Activity Up to Week 36

Relapse was defined as the appearance of 3 or more new lesions a month (blisters, eczematous lesions, or urticarial plaques) or at least 1 large (\>10 centimeters \[cm\] diameter) eczematous lesion or urticarial plaque that does not heal within 1 week. Control of disease activity was defined as absence of new lesions and existing lesions beginning to heal. Participants who used rescue treatment were considered to have relapsed after achieving control of disease activity. Participants whose response status could not be determined due to missing data were considered to have relapsed after achieving control of disease activity.

Time frame:
Up to Week 36
Reported as:
Number · Percentage of Participants
Percent of Participants Who Relapsed After Achieving Control of Disease Activity Up to Week 36
Percentage of ParticipantsPlaceboDupilumab Q2W
Percent of Participants Who Relapsed After Achieving Control of Disease Activity Up to Week 3691.873.1
Statistical analysis
  • Placebo vs Dupilumab Q2W · Barnard's exact test · p = 0.0165 · Risk difference (rd): -18.8 · 95% CI -33.52 to -4.05Dupilumab minus Placebo
SecondaryPercent of Participants Who Did Not Achieve Complete Remission Before Week 36

Complete remission was defined as absence of new lesions and epithelialization of old lesions. Participants who achieved initial complete remission after rescue treatment use were considered to not have achieved complete remission before week 36. Participants whose response status could not be determined due to missing data were considered to not have achieved complete remission before week 36.

Time frame:
Up to Week 36
Reported as:
Number · Percentage of Participants
Percent of Participants Who Did Not Achieve Complete Remission Before Week 36
Percentage of ParticipantsPlaceboDupilumab Q2W
Percent of Participants Who Did Not Achieve Complete Remission Before Week 3650.939.6
Statistical analysis
  • Placebo vs Dupilumab Q2W · Barnard's exact test · p = 0.2758 · Risk difference (rd): -11.3 · 95% CI -29.52 to 7.67Dupilumab minus Placebo
SecondaryPercent of Participants Achieving a Reduction in BPDAI Activity Score of ≥50% From Baseline to Week 36

BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 36 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.

Time frame:
Baseline, Week 36
Reported as:
Number · Estimated Percentage of Participants
Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥50% From Baseline to Week 36
Estimated Percentage of ParticipantsPlaceboDupilumab Q2W
Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥50% From Baseline to Week 3613.241.0
Statistical analysis
  • Placebo vs Dupilumab Q2W · Barnard's exact test · p = 0.0012 · Risk difference (rd): 27.8 · 95% CI 11.13 to 43.56Dupilumab minus Placebo
SecondaryPercent of Participants Achieving a Reduction in BPDAI Activity Score of ≥75% From Baseline to Week 36

BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 36 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.

Time frame:
Baseline, Week 36
Reported as:
Number · Estimated Percentage of Participants
Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥75% From Baseline to Week 36
Estimated Percentage of ParticipantsPlaceboDupilumab Q2W
Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥75% From Baseline to Week 3612.538.8
Statistical analysis
  • Placebo vs Dupilumab Q2W · Barnard's exact test · p = 0.0024 · Risk difference (rd): 26.3 · 95% CI 9.68 to 42.11Dupilumab minus Placebo
SecondaryPercent of Participants Achieving a Reduction in BPDAI Activity Score of ≥90% From Baseline to Week 36

BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 36 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.

Time frame:
Baseline, Week 36
Reported as:
Number · Estimated Percentage of Participants
Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥90% From Baseline to Week 36
Estimated Percentage of ParticipantsPlaceboDupilumab Q2W
Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥90% From Baseline to Week 369.838.6
Statistical analysis
  • Placebo vs Dupilumab Q2W · Barnard's exact test · p = 0.0006 · Risk difference (rd): 28.8 · 95% CI 12.79 to 44.06Dupilumab minus Placebo
SecondaryChange in Autoimmune Bullous Disease Quality of Life (ABQOL) Score From Baseline to Week 36

ABQOL questionnaire consists of 17 items, which encompass physical burden of the disease, psychiatric effects, and effects on daily life functioning. Each question ranges from 0 to 3 points, with higher scores indicating poorer quality of life. The maximum ABQOL score is 51. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · Score on a Scale
Change in Autoimmune Bullous Disease Quality of Life (ABQOL) Score From Baseline to Week 36
Score on a ScalePlaceboDupilumab Q2W
Change in Autoimmune Bullous Disease Quality of Life (ABQOL) Score From Baseline to Week 36-3.41 ± 1.492-7.09 ± 1.458
Statistical analysis
  • Placebo vs Dupilumab Q2W · ANCOVA · p = 0.0476 · Ls mean difference: -3.68 · 95% CI -7.320 to -0.039Dupilumab minus Placebo
SecondaryChange in Percent Body Surface Area (BSA) of BP Involvement From Baseline to Week 36

Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · Percent BSA
Change in Percent Body Surface Area (BSA) of BP Involvement From Baseline to Week 36
Percent BSAPlaceboDupilumab Q2W
Change in Percent Body Surface Area (BSA) of BP Involvement From Baseline to Week 36-17.51 ± 2.544-24.07 ± 2.411
Statistical analysis
  • Placebo vs Dupilumab Q2W · ANCOVA · p = 0.0345 · Ls mean difference: -6.57 · 95% CI -12.659 to -0.478Dupilumab minus Placebo
SecondaryChange in BP180 Immunoglobulin G (IgG) Autoantibody Titer From Baseline to Week 36

Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · units per milliliter (U/mL)
Change in BP180 Immunoglobulin G (IgG) Autoantibody Titer From Baseline to Week 36
units per milliliter (U/mL)PlaceboDupilumab Q2W
Change in BP180 Immunoglobulin G (IgG) Autoantibody Titer From Baseline to Week 36-137.57 ± 57.125-136.33 ± 53.247
Statistical analysis
  • Placebo vs Dupilumab Q2W · ANCOVA · p = 0.9857 · Ls mean difference: 1.23 · 95% CI -133.738 to 136.207Dupilumab minus Placebo
SecondaryChange in BP230 IgG Autoantibody Titer From Baseline to Week 36

Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · U/mL
Change in BP230 IgG Autoantibody Titer From Baseline to Week 36
U/mLPlaceboDupilumab Q2W
Change in BP230 IgG Autoantibody Titer From Baseline to Week 36-33.91 ± 29.380-18.49 ± 27.705
Statistical analysis
  • Placebo vs Dupilumab Q2W · ANCOVA · p = 0.6680 · Ls mean difference: 15.42 · 95% CI -55.036 to 85.872Dupilumab minus Placebo
SecondaryPercent of Participants Achieving Sustained Remission at Week 52

Sustained remission at week 52, defined as: (1) Complete remission (absence of new lesions \& epithelialization of old lesions) \& off OCS no later than week 16 \& (2) Absence of disease relapse (appearance of ≥3 new lesions a month \[blisters, eczematous lesions, or urticarial plaques\] or at least 1 large eczematous lesion or urticarial plaque that does not heal within 1 week) after completion of OCS taper, no later than week 16, to week 52 \& (3) Absence of need for rescue therapy during 52 weeks (rescue therapy includes increase of OCS dose during the taper, re-initiation of OCS after completion of the OCS taper, or initiation of any BP-directed therapy). Participants with missing sustained remission data at week 52 due to discontinuation due to lack of efficacy, treatment-related AE, or death were considered non-responders \& those with missing data due to other reasons were handled using multiple imputation.

Time frame:
At Week 52
Reported as:
Number · Estimated Percentage of Participants
Percent of Participants Achieving Sustained Remission at Week 52
Estimated Percentage of ParticipantsPlaceboDupilumab Q2W
Percent of Participants Achieving Sustained Remission at Week 524.014.2
Statistical analysis
  • Placebo vs Dupilumab Q2W · Barnard's exact test · p = 0.0736 · Risk difference (rd): 10.2 · 95% CI -1.35 to 23.11Dupilumab minus Placebo
SecondaryTotal Cumulative Dose of OCS From Baseline to Week 52

All participants in both treatment groups were started on OCS at randomization (day 1) with taper beginning no later than week 6 with the objective to taper off by week 16. OCS could be used as rescue treatment for loss of disease control/ disease relapse during the study. Days after non-OCS systemic rescue treatment use were imputed by the WOCF method (i.e., the highest daily OCS dose prior to any non-OCS systemic rescue treatment use). Missing data after study discontinuation were imputed with the average daily OCS dose among week 52 completers in each treatment group.

Time frame:
Week 52
Reported as:
Least squares mean · mg
Total Cumulative Dose of OCS From Baseline to Week 52
mgPlaceboDupilumab Q2W
Total Cumulative Dose of OCS From Baseline to Week 527159.09 ± 820.1445133.03 ± 788.414
Statistical analysis
  • Placebo vs Dupilumab Q2W · ANCOVA · p = 0.0463 · Ls mean difference: -2026.06 · 95% CI -4018.490 to -33.624Dupilumab minus Placebo
SecondaryDuration of Complete Remission While Not Requiring OCS Up to Week 52

Complete remission was defined as absence of new lesions and epithelialization of old lesions. Participants were considered as not achieving complete remission after rescue treatment use. Participants with missing assessment of complete remission caused by discontinuation from the study before week 52 due to lack of efficacy, treatment-related AE, or death were considered as not achieving complete remission. Participants with missing assessment of complete remission due to other reasons were imputed using multiple imputation.

Time frame:
Up to Week 52
Reported as:
Least squares mean · Days
Duration of Complete Remission While Not Requiring OCS Up to Week 52
DaysPlaceboDupilumab Q2W
Duration of Complete Remission While Not Requiring OCS Up to Week 5224.7 ± 15.1167.2 ± 14.13
Statistical analysis
  • Placebo vs Dupilumab Q2W · ANCOVA · p = 0.0198 · Ls mean difference: 42.5 · 95% CI 6.77 to 78.24Dupilumab minus Placebo
SecondaryPercent of Participants Who Did Not Achieve Control of Disease Activity Before Week 52

Control of disease activity was defined as absence of new lesions and existing lesions beginning to heal. Participants who achieved initial control of disease activity after rescue treatment use were considered to not have achieved control of disease activity before week 52. Participants whose response status could not be determined due to missing data were considered to not have achieved control of disease activity before week 52.

Time frame:
Up to Week 52
Reported as:
Number · Percentage of Participants
Percent of Participants Who Did Not Achieve Control of Disease Activity Before Week 52
Percentage of ParticipantsPlaceboDupilumab Q2W
Percent of Participants Who Did Not Achieve Control of Disease Activity Before Week 527.51.9
Statistical analysis
  • Placebo vs Dupilumab Q2W · Barnard's exact test · p = 0.2414 · Risk difference (rd): -5.7 · 95% CI -16.31 to 3.34Dupilumab minus Placebo
SecondaryPercent of Participants Who Relapsed After Achieving Control of Disease Activity Up to Week 52

Relapse was defined as the appearance of 3 or more new lesions a month (blisters, eczematous lesions, or urticarial plaques) or at least 1 large (\>10 cm diameter) eczematous lesion or urticarial plaque that does not heal within 1 week. Control of disease activity was defined as absence of new lesions and existing lesions beginning to heal. Participants who used rescue treatment were considered to have relapsed after achieving control of disease activity. Participants whose response status could not be determined due to missing data were considered to have relapsed after achieving control of disease activity.

Time frame:
Up to Week 52
Reported as:
Number · Percentage of Participants
Percent of Participants Who Relapsed After Achieving Control of Disease Activity Up to Week 52
Percentage of ParticipantsPlaceboDupilumab Q2W
Percent of Participants Who Relapsed After Achieving Control of Disease Activity Up to Week 5291.876.9
Statistical analysis
  • Placebo vs Dupilumab Q2W · Barnard's exact test · p = 0.0461 · Risk difference (rd): -14.9 · 95% CI -29.39 to -0.65Dupilumab minus Placebo
SecondaryPercent of Participants Who Did Not Achieve Complete Remission Before Week 52

Complete remission was defined as absence of new lesions and epithelialization of old lesions. Participants who achieved initial complete remission after rescue treatment use were considered to not have achieved complete remission before week 52. Participants whose response status could not be determined due to missing data were considered to not have achieved complete remission before week 52.

Time frame:
Up to Week 52
Reported as:
Number · Percentage of Participants
Percent of Participants Who Did Not Achieve Complete Remission Before Week 52
Percentage of ParticipantsPlaceboDupilumab Q2W
Percent of Participants Who Did Not Achieve Complete Remission Before Week 5250.934.0
Statistical analysis
  • Placebo vs Dupilumab Q2W · Barnard's exact test · p = 0.0843 · Risk difference (rd): -17.0 · 95% CI -34.74 to 1.93Dupilumab minus Placebo
SecondaryPercent Change in Weekly Average of Daily Peak Pruritus NRS From Baseline to Week 52

Peak pruritus NRS was used by participants to rate the intensity of pruritus during the past 24 hours, with 0 indicating no itch and 10 indicating worst itch possible. Participants were required to have a baseline peak pruritus NRS maximum intensity average of ≥4 during the 7 days prior to randomization for eligibility. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 52. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Percentage of Change
Percent Change in Weekly Average of Daily Peak Pruritus NRS From Baseline to Week 52
Percentage of ChangePlaceboDupilumab Q2W
Percent Change in Weekly Average of Daily Peak Pruritus NRS From Baseline to Week 52-23.4 ± 6.41-53.0 ± 6.44
Statistical analysis
  • Placebo vs Dupilumab Q2W · ANCOVA · p = 0.0002 · Ls mean difference: -29.5 · 95% CI -45.23 to -13.80Dupilumab minus Placebo
SecondaryPercent of Participants With Improvement (Reduction) of Weekly Average of Daily Peak Pruritus NRS ≥4 From Baseline to Week 52

Peak pruritus NRS was used by participants to rate the intensity of pruritus during the past 24 hours, with 0 indicating no itch and 10 indicating worst itch possible. Participants were required to have a baseline peak pruritus NRS maximum intensity average of ≥4 during the 7 days prior to randomization for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 52 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the weekly average of daily peak pruritus NRS.

Time frame:
Baseline, Week 52
Reported as:
Number · Estimated Percentage of Participants
Percent of Participants With Improvement (Reduction) of Weekly Average of Daily Peak Pruritus NRS ≥4 From Baseline to Week 52
Estimated Percentage of ParticipantsPlaceboDupilumab Q2W
Percent of Participants With Improvement (Reduction) of Weekly Average of Daily Peak Pruritus NRS ≥4 From Baseline to Week 528.336.4
Statistical analysis
  • Placebo vs Dupilumab Q2W · Barnard's exact test · p = 0.0006 · Risk difference (rd): 28.1 · 95% CI 12.44 to 43.55Dupilumab minus Placebo
SecondaryPercent Change in BPDAI Activity Score From Baseline to Week 52

BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 52. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Percentage of Change
Percent Change in BPDAI Activity Score From Baseline to Week 52
Percentage of ChangePlaceboDupilumab Q2W
Percent Change in BPDAI Activity Score From Baseline to Week 52-49.1 ± 7.02-76.1 ± 6.85
Statistical analysis
  • Placebo vs Dupilumab Q2W · ANCOVA · p = 0.0014 · Ls mean difference: -27.0 · 95% CI -43.54 to -10.37Dupilumab minus Placebo
SecondaryPercent of Participants Achieving a Reduction in BPDAI Activity Score of ≥50% From Baseline to Week 52

BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 52 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.

Time frame:
Baseline, Week 52
Reported as:
Number · Estimated Percentage of Participants
Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥50% From Baseline to Week 52
Estimated Percentage of ParticipantsPlaceboDupilumab Q2W
Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥50% From Baseline to Week 5211.237.2
Statistical analysis
  • Placebo vs Dupilumab Q2W · Barnard's exact test · p = 0.0019 · Risk difference (rd): 25.9 · 95% CI 9.86 to 41.36Dupilumab minus Placebo
SecondaryPercent of Participants Achieving a Reduction in BPDAI Activity Score of ≥75% From Baseline to Week 52

BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 52 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.

Time frame:
Baseline, Week 52
Reported as:
Number · Estimated Percentage of Participants
Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥75% From Baseline to Week 52
Estimated Percentage of ParticipantsPlaceboDupilumab Q2W
Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥75% From Baseline to Week 5210.636.6
Statistical analysis
  • Placebo vs Dupilumab Q2W · Barnard's exact test · p = 0.0016 · Risk difference (rd): 26.0 · 95% CI 10.05 to 41.40Dupilumab minus Placebo
SecondaryPercent of Participants Achieving a Reduction in BPDAI Activity Score of ≥90% From Baseline to Week 52

BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 52 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.

Time frame:
Baseline, Week 52
Reported as:
Number · Estimated Percentage of Participants
Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥90% From Baseline to Week 52
Estimated Percentage of ParticipantsPlaceboDupilumab Q2W
Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥90% From Baseline to Week 529.934.4
Statistical analysis
  • Placebo vs Dupilumab Q2W · Barnard's exact test · p = 0.0024 · Risk difference (rd): 24.5 · 95% CI 8.89 to 39.75Dupilumab minus Placebo
SecondaryChange in ABQOL Score From Baseline to Week 52

ABQOL questionnaire consists of 17 items, which encompass physical burden of the disease, psychiatric effects, and effects on daily life functioning. Each question ranges from 0 to 3 points, with higher scores indicating poorer quality of life. The maximum ABQOL score is 51. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 52. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Score on a Scale
Change in ABQOL Score From Baseline to Week 52
Score on a ScalePlaceboDupilumab Q2W
Change in ABQOL Score From Baseline to Week 52-3.27 ± 1.508-7.29 ± 1.465
Statistical analysis
  • Placebo vs Dupilumab Q2W · ANCOVA · p = 0.0311 · Ls mean difference: -4.02 · 95% CI -7.680 to -0.365Dupilumab minus Placebo
SecondaryChange in Percent BSA of BP Involvement From Baseline to Week 52

Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 52. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Percent BSA
Change in Percent BSA of BP Involvement From Baseline to Week 52
Percent BSAPlaceboDupilumab Q2W
Change in Percent BSA of BP Involvement From Baseline to Week 52-16.59 ± 2.588-23.89 ± 2.445
Statistical analysis
  • Placebo vs Dupilumab Q2W · ANCOVA · p = 0.0206 · Ls mean difference: -7.30 · 95% CI -13.470 to -1.122Dupilumab minus Placebo
SecondaryChange in BP180 IgG Autoantibody Titer From Baseline to Week 52

Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 52. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · U/mL
Change in BP180 IgG Autoantibody Titer From Baseline to Week 52
U/mLPlaceboDupilumab Q2W
Change in BP180 IgG Autoantibody Titer From Baseline to Week 52-133.02 ± 57.248-137.60 ± 53.315
Statistical analysis
  • Placebo vs Dupilumab Q2W · ANCOVA · p = 0.9471 · Ls mean difference: -4.58 · 95% CI -139.885 to 130.728Dupilumab minus Placebo
SecondaryChange in BP230 IgG Autoantibody Titer From Baseline to Week 52

Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 52. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · U/mL
Change in BP230 IgG Autoantibody Titer From Baseline to Week 52
U/mLPlaceboDupilumab Q2W
Change in BP230 IgG Autoantibody Titer From Baseline to Week 52-33.33 ± 29.392-18.83 ± 27.802
Statistical analysis
  • Placebo vs Dupilumab Q2W · ANCOVA · p = 0.6876 · Ls mean difference: 14.49 · 95% CI -56.142 to 85.130Dupilumab minus Placebo
SecondaryPercent of Participants in Complete Remission and Off OCS No Later Than Week 16

Complete remission was defined as absence of new lesions and epithelialization of old lesions. Participants were considered non-responders after rescue treatment use. Participants with missing assessment of complete remission caused by discontinuation from the study before week 16 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Participants with missing assessment of complete remission before week 16 due to other reasons were imputed using multiple imputation.

Time frame:
Up to Week 16
Reported as:
Number · Estimated Percentage of Participants
Percent of Participants in Complete Remission and Off OCS No Later Than Week 16
Estimated Percentage of ParticipantsPlaceboDupilumab Q2W
Percent of Participants in Complete Remission and Off OCS No Later Than Week 1626.634.6
Statistical analysis
  • Placebo vs Dupilumab Q2W · Barnard's exact test · p = 0.5283 · Risk difference (rd): 8.0 · 95% CI -9.75 to 25.35Dupilumab minus Placebo
SecondaryPercent Change in BPDAI Activity Score From Baseline to Week 16

BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Percentage of Change
Percent Change in BPDAI Activity Score From Baseline to Week 16
Percentage of ChangePlaceboDupilumab Q2W
Percent Change in BPDAI Activity Score From Baseline to Week 16-56.3 ± 7.02-78.5 ± 6.88
Statistical analysis
  • Placebo vs Dupilumab Q2W · ANCOVA · p = 0.0088 · Ls mean difference: -22.2 · 95% CI -38.89 to -5.61Dupilumab minus Placebo
SecondaryPercent of Participants Achieving a Reduction in BPDAI Activity Score of ≥50% From Baseline to Week 16

BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 16 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.

Time frame:
Baseline, Week 16
Reported as:
Number · Estimated Percentage of Participants
Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥50% From Baseline to Week 16
Estimated Percentage of ParticipantsPlaceboDupilumab Q2W
Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥50% From Baseline to Week 1645.267.3
Statistical analysis
  • Placebo vs Dupilumab Q2W · Barnard's exact test · p = 0.0250 · Risk difference (rd): 22.1 · 95% CI 3.04 to 39.66Dupilumab minus Placebo
SecondaryPercent of Participants Achieving a Reduction in BPDAI Activity Score of ≥75% From Baseline to Week 16

BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 16 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.

Time frame:
Baseline, Week 16
Reported as:
Number · Estimated Percentage of Participants
Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥75% From Baseline to Week 16
Estimated Percentage of ParticipantsPlaceboDupilumab Q2W
Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥75% From Baseline to Week 1637.159.4
Statistical analysis
  • Placebo vs Dupilumab Q2W · Barnard's exact test · p = 0.0250 · Risk difference (rd): 22.4 · 95% CI 3.09 to 40.08Dupilumab minus Placebo
SecondaryPercent of Participants Achieving a Reduction in BPDAI Activity Score of ≥90% From Baseline to Week 16

BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 16 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.

Time frame:
Baseline, Week 16
Reported as:
Number · Estimated Percentage of Participants
Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥90% From Baseline to Week 16
Estimated Percentage of ParticipantsPlaceboDupilumab Q2W
Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥90% From Baseline to Week 1632.745.8
Statistical analysis
  • Placebo vs Dupilumab Q2W · Barnard's exact test · p = 0.2089 · Risk difference (rd): 13.1 · 95% CI -5.79 to 31.13Dupilumab minus Placebo
SecondaryPercent Change in Weekly Average of Daily Peak Pruritus NRS From Baseline to Week 16

Peak pruritus NRS was used by participants to rate the intensity of pruritus during the past 24 hours, with 0 indicating no itch and 10 indicating worst itch possible. Participants were required to have a baseline peak pruritus NRS maximum intensity average of ≥4 during the 7 days prior to randomization for eligibility. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Percentage of Change
Percent Change in Weekly Average of Daily Peak Pruritus NRS From Baseline to Week 16
Percentage of ChangePlaceboDupilumab Q2W
Percent Change in Weekly Average of Daily Peak Pruritus NRS From Baseline to Week 16-36.4 ± 6.30-50.4 ± 6.35
Statistical analysis
  • Placebo vs Dupilumab Q2W · ANCOVA · p = 0.0767 · Ls mean difference: -14.0 · 95% CI -29.50 to 1.50Dupilumab minus Placebo
SecondaryPercent of Participants With Improvement (Reduction) of Weekly Average of Daily Peak Pruritus NRS ≥4 From Baseline to Week 16

Peak pruritus NRS was used by participants to rate the intensity of pruritus during the past 24 hours, with 0 indicating no itch and 10 indicating worst itch possible. Participants were required to have a baseline peak pruritus NRS maximum intensity average of ≥4 during the 7 days prior to randomization for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 16 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the weekly average of daily peak pruritus NRS.

Time frame:
Baseline, Week 16
Reported as:
Number · Estimated Percentage of Participants
Percent of Participants With Improvement (Reduction) of Weekly Average of Daily Peak Pruritus NRS ≥4 From Baseline to Week 16
Estimated Percentage of ParticipantsPlaceboDupilumab Q2W
Percent of Participants With Improvement (Reduction) of Weekly Average of Daily Peak Pruritus NRS ≥4 From Baseline to Week 1633.550.9
Statistical analysis
  • Placebo vs Dupilumab Q2W · Barnard's exact test · p = 0.0761 · Risk difference (rd): 17.4 · 95% CI -1.98 to 35.60Dupilumab minus Placebo
SecondaryNumber of Participants With At Least One Treatment-emergent Adverse Event (TEAE) Through Week 52
Time frame:
Through Week 52
Reported as:
Count of participants · Participants
Number of Participants With At Least One Treatment-emergent Adverse Event (TEAE) Through Week 52
ParticipantsPlaceboDupilumab Q2W
Number of Participants With At Least One Treatment-emergent Adverse Event (TEAE) Through Week 525151
SecondaryNumber of Participants With At Least One Serious TEAE Through Week 52
Time frame:
Through Week 52
Reported as:
Count of participants · Participants
Number of Participants With At Least One Serious TEAE Through Week 52
ParticipantsPlaceboDupilumab Q2W
Number of Participants With At Least One Serious TEAE Through Week 521612
SecondaryNumber of Participants With At Least One TE Adverse Event of Special Interest (AESI) Through Week 52
Time frame:
Through Week 52
Reported as:
Count of participants · Participants
Number of Participants With At Least One TE Adverse Event of Special Interest (AESI) Through Week 52
ParticipantsPlaceboDupilumab Q2W
Number of Participants With At Least One TE Adverse Event of Special Interest (AESI) Through Week 5204
SecondaryNumber of Participants With At Least One TEAE Through Week 64
Time frame:
Week 52 through Week 64
Reported as:
Count of participants · Participants
Number of Participants With At Least One TEAE Through Week 64
ParticipantsPlaceboDupilumab Q2W
Number of Participants With At Least One TEAE Through Week 642325
SecondaryNumber of Participants With At Least One Serious TEAE Through Week 64
Time frame:
Week 52 through Week 64
Reported as:
Count of participants · Participants
Number of Participants With At Least One Serious TEAE Through Week 64
ParticipantsPlaceboDupilumab Q2W
Number of Participants With At Least One Serious TEAE Through Week 6488
SecondaryNumber of Participants With At Least One TE AESI Through Week 64
Time frame:
Week 52 through Week 64
Reported as:
Count of participants · Participants
Number of Participants With At Least One TE AESI Through Week 64
ParticipantsPlaceboDupilumab Q2W
Number of Participants With At Least One TE AESI Through Week 6400
SecondaryConcentrations of Functional Dupilumab in Serum
Time frame:
Baseline to Week 64
Reported as:
Mean · milligrams per liter (mg/L)
Concentrations of Functional Dupilumab in Serum
milligrams per liter (mg/L)Dupilumab Q2W
Week 00 ± 0
Week 450.2 ± 26.2
Week 1666.7 ± 47.4
Week 3671.0 ± 60.0
Week 5278.6 ± 64.3
Week 648.73 ± 22.4
SecondaryNumber of Participants With TE Anti-drug Antibody (ADA) Response Per Maximum Titer Category
Time frame:
Baseline to Week 64
Reported as:
Count of participants · Participants
Number of Participants With TE Anti-drug Antibody (ADA) Response Per Maximum Titer Category
ParticipantsPlaceboDupilumab Q2W
TE Maximum Titer Low (<1,000)01
TE Maximum Titer Moderate (1,000 to 10,000)01
TE Maximum Titer High (>10,000)00
Other pre-specifiedSupplemental Analysis of Total Cumulative Dose of OCS From Baseline to Week 36

All participants in both treatment groups were started on OCS at randomization (day 1) with taper beginning no later than week 6 with the objective to taper off by week 16. OCS could be used as rescue treatment for loss of disease control/ disease relapse during the study. Days after non-OCS systemic rescue treatment use were imputed by the WOCF method (i.e., the highest daily OCS dose prior to any non-OCS systemic rescue treatment use). Missing data after study discontinuation were imputed with the average daily OCS dose among week 36 completers in each treatment group. Median total cumulative dose of OCS from baseline to week 36 reported.

Time frame:
Week 36
Reported as:
Median · mg
Supplemental Analysis of Total Cumulative Dose of OCS From Baseline to Week 36
mgPlaceboDupilumab Q2W
Supplemental Analysis of Total Cumulative Dose of OCS From Baseline to Week 364112.36 (3312.85 to 5158.25)2808.85 (1897.47 to 4115.00)
Statistical analysis
  • Placebo vs Dupilumab Q2W · Wilcoxon rank-sum test · p = 0.0003 · Hodges-lehmann estimator: -1244.06 · 95% CI -1850.535 to -646.435Dupilumab minus Placebo
Post-hocPost-Hoc Analysis of the Primary Endpoint as Per Health Authority: Percent of Participants Achieving Sustained Remission at Week 36

Sustained remission at week 36, defined as: (1) Complete remission (absence of new lesions \& epithelialization of old lesions) \& off oral corticosteroids (OCS) no later than week 16 \& (2) Absence of disease relapse (appearance of ≥3 new lesions a month \[blisters, eczematous lesions, or urticarial plaques\] or at least 1 large eczematous lesion or urticarial plaque that does not heal within 1 week) after completion of OCS taper, no later than week 16, to week 36 \& (3) Absence of need for rescue therapy during 36 weeks (rescue therapy includes increase of OCS dose during the taper, re-initiation of OCS after completion of the OCS taper, or initiation of any BP-directed therapy). Participants with missing sustained remission data at week 36 due to discontinuation due to lack of efficacy, treatment-related AE, or death were considered non-responders \& those with missing data due to other reasons were handled using multiple imputation.

Time frame:
At Week 36
Reported as:
Number · Estimated Percentage of Participants
Post-Hoc Analysis of the Primary Endpoint as Per Health Authority: Percent of Participants Achieving Sustained Remission at Week 36
Estimated Percentage of ParticipantsPlaceboDupilumab Q2W
Post-Hoc Analysis of the Primary Endpoint as Per Health Authority: Percent of Participants Achieving Sustained Remission at Week 366.118.3
Statistical analysis
  • Placebo vs Dupilumab Q2W · Barnard's exact test · p = 0.0645 · Risk difference (rd): 12.2 · 95% CI -0.79 to 26.10Dupilumab minus Placebo

Adverse events

Collected over From signing of informed consent through end of study (approximately 69 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo6/53 (11.3%)21/53 (39.6%)49/53 (92.5%)
Dupilumab Q2W2/53 (3.8%)20/53 (37.7%)43/53 (81.1%)
Most frequent serious events
Showing 10 of 67
Most frequent serious events
EventPlaceboDupilumab Q2W
PemphigoidSkin and subcutaneous tissue disorders3/533/53
PneumoniaInfections and infestations0/532/53
CellulitisInfections and infestations2/530/53
Urinary tract infectionInfections and infestations2/530/53
AnaemiaBlood and lymphatic system disorders2/530/53
Arthritis bacterialInfections and infestations0/531/53
Device related sepsisInfections and infestations0/531/53
Post procedural infectionInfections and infestations0/531/53
Staphylococcal skin infectionInfections and infestations0/531/53
UrosepsisInfections and infestations0/531/53
Most frequent other events
Showing 10 of 35
Most frequent other events
EventPlaceboDupilumab Q2W
PemphigoidSkin and subcutaneous tissue disorders12/536/53
NasopharyngitisInfections and infestations8/538/53
DiarrhoeaGastrointestinal disorders6/538/53
FallInjury, poisoning and procedural complications8/535/53
Oedema peripheralGeneral disorders7/538/53
Urinary tract infectionInfections and infestations2/535/53
ConjunctivitisInfections and infestations0/535/53
ArthralgiaMusculoskeletal and connective tissue disorders3/535/53
HeadacheNervous system disorders5/534/53
HypertensionVascular disorders5/534/53

Baseline characteristics

The full analysis set (FAS) included all randomized participants.

Age, Continuous
Age, Continuous(Years)PlaceboDupilumab Q2WTotal
Mean71.5 ± 9.5271.2 ± 10.0171.3 ± 9.72
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDupilumab Q2WTotal
Female243256
Male292150
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboDupilumab Q2WTotal
White373572
Black or African American112
Asian7916
American Indian or Alaska Native000
Native Hawaiian or Other Pacific Islander000
Other202
Not Reported6814
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboDupilumab Q2WTotal
Hispanic or Latino303
Not Hispanic or Latino424385
Unknown123
Not Reported7815
08

Study locations

53 sites
  • Regeneron study Site
    Birmingham, Alabama 35233, United States
  • Regeneron Study Site
    Scottsdale, Arizona 85259, United States
  • Regeneron Study Site
    Redwood City, California 94063, United States
  • Regeneron Study Site
    Farmington, Connecticut 06030, United States
  • Regeneron Study Site
    Miami, Florida 33125, United States
  • Regeneron study Site
    Orlando, Florida 32827, United States
  • Regeneron Study Site
    Iowa City, Iowa 52242, United States
  • Regeneron Study Site
    Boston, Massachusetts 02116, United States
  • Regeneron study Site
    Ann Arbor, Michigan 48109-5314, United States
  • Regeneron Study Site
    Chapel Hill, North Carolina 27516, United States
  • Regeneron Study Site
    Portland, Oregon 97239, United States
  • Regeneron Study Site
    Philadelphia, Pennsylvania 19104, United States
  • Regeneron study Site
    Providence, Rhode Island 02908, United States
  • Regeneron Study Site
    Murray, Utah 84107, United States
  • Regeneron study Site
    Charlottesville, Virginia 22903, United States
  • Regeneron Study Site
    Kogarah, New South Wales 2217, Australia
  • Regeneron Study Site
    Box Hill, Victoria 3128, Australia
  • Regeneron Study Site
    Bobigny, 93009, France
  • Regeneron Study Site
    Bordeaux, 33000, France
  • Regeneron Study Site
    Lille, 59037, France
  • Regeneron Study Site
    Nice, 06200, France
  • Regeneron Study Site
    Paris, 75010, France
  • Regeneron Study Site
    Rouen, 76031, France
  • Regeneron Study Site
    Münster, North Rhine-Westphal 48149, Germany
  • Regeneron Study Site
    Mainz, Rhineland-Palatinate 55131, Germany
  • Regeneron Study Site 2
    Dresden, Saxony 01307, Germany
  • Regeneron Study Site
    Lübeck, Schleswig-Holstein 23538, Germany
  • Regeneron Study Site
    Berlin, 10117, Germany
  • Regeneron Study Site
    Buxtehude, 21614, Germany
  • Regeneron Study Site
    Erlangen, 91054, Germany
  • Regeneron Study Site
    Freiburg im Breisgau, 79104, Germany
  • Regeneron Study site'
    Magdeburg, 39120, Germany
  • Regeneron Study site
    Marburg, 35043, Germany
  • Regeneron Study Site
    Munich, 80802, Germany
  • Regeneron Study Site
    Stuttgart, 70178, Germany
  • Regeneron study Site
    Afula, 1834111, Israel
  • Regeneron study Site
    Petah Tikva, 49100, Israel
  • Regeneron study Site
    Tel Aviv, 6423906, Israel
  • Regeneron Study site
    Kurume, Hukuoka 830-0011, Japan
  • Regeneron Study Site
    Hirosaki, 036-8563, Japan
  • Regeneron Study Site
    Ichinomiya, 491-8558, Japan
  • Regeneron Study Site
    Osaka, 545-8586, Japan
  • Regeneron Study Site
    Sapporo, 060-8648, Japan
  • Regeneron Study Site
    Tokyo, 160-8582, Japan
  • Regeneron Study Site
    Krakow, Lesser Poland Voivodeship 31-147, Poland
  • Regeneron Study site'
    Ossy, 42-624, Poland
  • Regeneron Study site'
    Wroclaw, 50566, Poland
  • Regeneron Study Site
    Badalona, Barcelona 08916, Spain
  • Regeneron Study Site
    Madrid, 28034, Spain
  • Regeneron study Site
    Madrid, 28046, Spain
  • Regeneron study Site
    Pamplona, 31008, Spain
  • Regeneron study Site
    Taipei, Zhongzheng District 10002, Taiwan
  • Regeneron study Site
    Taoyuan City, 33305, Taiwan
09

References and documents

Publications

  • Murrell DF, Joly P, Werth VP, Ujiie H, Worm M, Mangold AR, Avetisova E, Maloney J, Laws E, Mortensen E, Dubost-Brama A, Shabbir A. Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT. Adv Ther. 2024 Jul;41(7):2991-3002. doi: 10.1007/s12325-024-02810-3. Epub 2024 Mar 5. PubMed 38443648 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All individual patient data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Jul 2024, 44 months.

Results were first posted in Mar 2026, 1 year 7 months after primary completion. A results delay was requested in Jul 2025.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2019
First posted
Dec 20, 2019
StartActual
Oct 28, 2020
Primary completionActual
Jul 12, 2024
CompletionActual
Jan 5, 2025
Results delay requested
Jul 11, 2025
Results first posted
Mar 6, 2026
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04206553
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Dec 20, 2019
Start date
Oct 28, 2020
Primary completion
Jul 12, 2024
Completion
Jan 5, 2025
Results posted
Mar 6, 2026
Last update
Jun 18, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion